Funding profile · Pharmacy technology

NimbleRx

Eleven years of venture fundraising left a single Form D on the SEC record. It covers a 2022 offering that was never reported as closed, and it is the only filing under the company’s own CIK. Swoop acquired the business on May 26, 2026.

$14.7MSold of $25.0M offered, Form D filed Jun 14, 2022
$60MTotal venture capital raised as reported by September 2019
9Investors of record on the 2022 Form D, about $1.64M each
1Form D on file, covering roughly eleven years of fundraising

Data as of September 24, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2015 Y Combinator, then angel and seed Not disclosed Y Combinator; Sequoia partnered in 2015 per its own site Investor page
Oct 2017 Round led by Sequoia Capital $28,000,000 Sequoia Capital lead; Y Combinator, First Round Capital, DAG Ventures, Khosla Ventures CNBC
By Sep 2019 Cumulative to date $60,000,000 Same group. Forge also lists Felicis, Four Rivers, Glade Brook, Liquid 2, Northgate and SV Angel Independent
May to Jun 2022 Equity offering, Rule 506(b) $14,749,877 sold of $25,000,000 offered 9 accredited investors, not named Form D
May 26, 2026 Acquisition by Swoop Terms not disclosed Swoop, a Real Chemistry spin-off Release

What the filings show

Nimble Rx, Inc. · Form D · filed Jun 14, 2022

First sale
May 31, 2022
Offered
$25,000,000 equity
Sold
$14,749,877 · $10,250,123 remaining
Investors
9 · average about $1,638,875 · no non-accredited investors
Exemption
Rule 506(b) · offering duration one year or less
Fees
Sales commissions $0 · finders fees $0
Revenue range
Decline to disclose
Related persons
Talha Waqar (executive officer, director), signing as CEO; Young Chung (director); Farouk Ladha (director)
Filing
SEC EDGAR, CIK 0001933654, Redwood City, CA, incorporated in Delaware

Reading the filings

  1. The checks were institutional.Nine investors put in $14,749,877, an average of about $1,638,875 each. No non-accredited investors were admitted and no commissions or finders fees were paid, which points to a priced round with named funds rather than a syndicate or a broker-assisted raise.
  2. The offering was never reported as complete.$10,250,123 of the $25,000,000 was still unsold at filing, or 41 percent. No amendment has been filed in the four years since, so the public record does not show whether the balance was ever raised. The offering was declared to run one year or less, so that window closed in 2023.
  3. Form D undercounts this company badly.The CIK was created in 2022 and holds one filing. The $28 million round of October 2017 and the roughly $60 million reported by September 2019 have no Form D at all. Issuers raising under Section 4(a)(2) file none, so the gap does not mean the money did not move; it means the SEC record is not where this company’s history lives.
  4. The issuer declined to state revenue.In 2019 the company publicly claimed a $150 million annual run rate, and in November 2019 the founder said roughly $200 million. Three years later the Form D selected “Decline to Disclose” for revenue range. Both are permitted; together they mean no verified revenue figure exists in any public record.
  5. The signature name differs from the press name.The filing lists Talha Waqar as executive officer and director and carries his signature as CEO. Press coverage from 2017 to 2026 names the founder and CEO as Talha Sattar. Both names appear as authorized official across the nine NPPES pharmacy records for Nimble Pharmacy Inc, which is consistent with one person and two recorded forms of the name.
  6. The board was three people.Only Talha Waqar, Young Chung and Farouk Ladha are listed. For a company that had taken money from Sequoia, Khosla, First Round and DAG, a three-seat board is small, and the filing does not identify which investor, if any, either director represents.

Commercial signals

Signal Detail Source type
Exit Acquired by Swoop, announced May 26, 2026. Terms not disclosed. Marketed since as SwoopRx by Nimble. Company-stated
Licensure Nine NPPES pharmacy enumerations for Nimble Pharmacy Inc, 2015 to 2018, with state permit numbers in California, Arizona, Texas and Washington. The dispensing stores closed in early 2019. Public record
Regulatory position Named in a House Judiciary Committee report of Jan 21, 2026 as a digital hub, and in internal CVS documents as a competitive threat. CVS provider manual changes targeting hub-using pharmacies are a live channel risk. Public record
Customers Bartell Drugs, Parkside Compounding Pharmacy, Saint Peters Community Pharmacy, Dave Randolph Pharmacies, and the Independent Pharmacy Cooperative from June 2026. Company and partner
Scale All 50 states and more than 7,000 storefronts, 16 million patients (May 2026). Nimble’s own pharmacies page said “hundreds of independent retail pharmacies” on Sep 24, 2026. Figures disagree
Unit economics $3.4 million paid to pharmacies in Experience Payments in 2025, on 25 percent of pharmacy volume, per the cooperative vendor page. No take rate, gross margin or revenue has been published. Partner-stated

What to watch

  • An amended Form D, or a new one from Swoop, which would settle whether the 2022 balance was raised.
  • Any disclosure of acquisition terms. Neither party has given a price, and Swoop is private.
  • Whether the founder retains the president title he held in June 2026, one month after the deal closed.
  • A reconciled pharmacy count and any published revenue figure.
  • Deactivation of the nine dormant pharmacy NPIs, which would close out the dispensing chapter on the federal record.

The NimbleRx story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Bunkerhill Health: Shared investor: Felicis. Nine FDA-cleared imaging and ECG algorithms, most built inside academic medical centers, wrapped in a platform that acts on what they find
  • Comprehend Systems: Shared investor: Sequoia. A Y Combinator company that sold software for watching clinical trials while they were still running
  • Veera Health: Shared investor: Sequoia. An online clinic for polycystic ovary syndrome, built in Mumbai in 2020 and funded by Y Combinator and Sequoia Surge
  • Clara: Shared investor: Liquid 2. An AI powered primary care practice built by the founders who scaled Circle Medical to nine figures in revenue

Sources

  1. Public recordForm D, Nimble Rx, Inc., CIK 0001933654SEC EDGAR · Jun 14, 2022
  2. Public recordNPPES NPI Registry, Nimble Pharmacy, nine recordsCMS · queried Sep 24, 2026
  3. Public recordWhen CVS Writes the RulesUS House Committee on the Judiciary · Jan 21, 2026
  4. IndependentNimble drug delivery startup scores $28 million in fundingCNBC, Christina Farr · Oct 23, 2017
  5. IndependentA buzzy startup raised $60 million to give hundreds of independent pharmacies a new weaponBusiness Insider · Sep 13, 2019
  6. InterviewThought Leaders in E-Commerce: Talha Sattar, CEO of NimbleRxSramana Mitra · Nov 25, 2019
  7. IndependentNimble Rx financing details and investor listForge Global · accessed Sep 24, 2026
  8. IndependentReal Chemistry spin-off Swoop acquires NimblePRWeek, Bella Czajkowski · May 27, 2026
  9. IndependentSwoop acquires prescription fulfillment platform NimbleFierce Healthcare, Cailey Gleeson · May 26, 2026
  10. CompanySwoop Acquires NimbleBusiness Wire · May 26, 2026
  11. CompanyIndependent Pharmacy Cooperative and NimbleRx Team UpNimbleRx · Jun 17, 2026
  12. PartnerNimbleRx vendor page with Experience Payments figuresIndependent Pharmacy Cooperative · accessed Sep 24, 2026

Compiled from SEC, CMS and congressional public records and published reports as of September 24, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in NimbleRx. This page is not an offer to sell or a recommendation to buy any security.